Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is GBX 2,325 ($30.57).
A number of research firms have recently commented on HIK. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 2,750 ($36.16) target price on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Berenberg Bank raised Hikma Pharmaceuticals to a “buy” rating and upped their price objective for the company from GBX 2,100 ($27.61) to GBX 2,400 ($31.56) in a research report on Monday.
Get Our Latest Analysis on HIK
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals Cuts Dividend
The firm also recently disclosed a dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, August 15th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a dividend yield of 1.37%. Hikma Pharmaceuticals’s dividend payout ratio is presently 9,538.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- What is the S&P/TSX Index?
- Emerging Markets: What They Are and Why They Matter
- Investing In Automotive Stocks
- Recession or Not, These 3 Stocks Are Winners
- Industrial Products Stocks Investing
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.